Qure.ai, a global healthcare AI provider, has received a Health Canada Class III medical device licence for its suite of medical imaging AI solutions.
The approval will allow the company to introduce its AI-powered tools, aimed at helping clinicians enhance patient care, to the Canadian healthcare market.
Health Canada's Class III classification demonstrates a thorough evaluation process and endorses the safety, efficacy and quality of Qure.ai's AI solution.
This classification is the highest risk category for software-as-medical-device (SaMD) products, highlighting the advanced capabilities of Qure.ai's algorithms and stringent safety protocols in the medical imaging field.
Qure.ai's solutions are designed to support diagnostic accuracy and efficiency, contributing to improved patient outcomes through earlier detection of disease conditions.
The Class III license includes all of Qure.ai's core services, including qXR, an AI tool for chest x-ray analysis that can detect a range of abnormalities and prioritize cases for consideration.
Access the most comprehensive company profiles on the market from GlobalData. Save time on research and gain a competitive advantage.
Company Profile – Free Sample
You will receive a download email shortly
We are confident in the unique quality of our company profiles, but because we want you to make the most beneficial decision for your business, we are offering free samples that you can download by submitting the form below.
From GlobalData
Other solutions include qCT, which helps manage pulmonary nodules in chest CT scans for lung cancer screening and monitoring, and qER, which helps quickly identify strokes, traumatic brain injuries, and other neurological issues.
Additionally, Qure.ai's solutions facilitate accurate detection and measurement of endotracheal and tracheostomy tube placement, identification of pneumothorax, and triage of significant findings using plain chest radiographs.
The Qure app enhances lung oncology and radiology workflows, allowing clinicians to remotely view and diagnose scans including X-ray, CT and MR.
These AI-powered tools are designed to streamline patient care, provide critical alerts and support early intervention to improve outcomes in both pre-hospital and emergency settings.
“Achieving a Class III license from Health Canada is a testament to the rigor and quality of our AI algorithms,” said Prashant Warrier, co-founder and CEO of Qure.ai.
“This approval enables us to bring our globally proven AI solutions to the Canadian healthcare market and support healthcare professionals in making faster, more accurate and more efficient diagnoses, putting patient care at the heart of digital healthcare transformation.”
In 2022, the U.S. Food and Drug Administration (FDA) granted 510(k) clearance to Qure.ai's AI algorithm, qXR-BT.
